PT Dexa Medica recently hosted a webinar titled "Natural Oral Fibrinolytic to Overcome Thrombosis," which focused on the benefits of DISOLF (DLBS1033) in managing various thrombosis-related diseases.
The event was inaugurated by PT Dexa Medica Director, Mrs. Gracianti Soetikno Pandji, who emphasized that Dexa Group's natural medicine development aligns with its core values of Expertise for the Promotion of Health.
"All natural medicines are developed at DLBS (Dexa Laboratories of Biomolecular Sciences), initiated by the founder of Dexa Group to treat illnesses using natural-based solutions," stated Mrs. Gracianti during the webinar held on Saturday, July 11, 2020.
Dexa Group Co-founder Mrs. Hetty Soetikno also attended the virtual discussion. Key speakers included DLBS Molecular Pharmacologist Dr. Raymond Tjandrawinata, Cambodian cardiologist Dr. Liv Chinh, and Vice President of the Philippine Society of Diabetologists (PSD) Dr. Danilo Baldemor. The webinar attracted participation from doctors in the Philippines and Cambodia.
Dr. Raymond explained that DISOLF is derived from the serine protease enzyme fraction extracted from earthworms (Lumbricus rubellus), a species abundant in Indonesia.
"Lumbrokinase DLBS1033 is a standardized biotechnological protein product, comprising bioactive protein fractions purified through advanced biotechnology processes known as TCEBS," he noted.
TCEBS (Tandem Chemistry Expression Bioassay System) is a systematic screening methodology identifying the most potent and active candidates for new product development. This system is complemented by bioassays leveraging gene expression and protein array techniques.
"With its low molecular weight, DLBS1033 can penetrate deep into thrombi and dissolve blood clots effectively," Dr. Raymond added.
The second speaker, Dr. Liv Chinh, presented on thrombosis management and shared a case study involving a patient with deep vein thrombosis (DVT).
"We treated a patient with DVT using DLBS1033 for 14 days. The patient showed complete resolution of thrombotic occlusion in the veins without bleeding complications," he reported.
Meanwhile, the third speaker, Dr. Danilo Baldemor, discussed managing peripheral arterial disease (PAD) caused by diabetes using DISOLF. He highlighted how PAD treatment with DISOLF can protect patients from the risk of stroke.
"DISOLF contains natural enzymes with potent thrombolytic effects, enhancing lower limb circulation in PAD patients," Dr. Baldemor explained.
DISOLF (DLBS1033) is a flagship Indonesian Indigenous Modern Medicine (Obat Modern Asli Indonesia (OMAI)) that has been clinically proven to support blood circulation effectively.